AGGXinactive
ANGIOGENEX, INC.
Biopharma developer (SEC filing verified)·Pre-clinical·CEO: Robert Benezra
OncologyOphthalmology
Run ANGIOGENEX, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ANGIOGENEX, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Governance
Frequently asked questions
Who is the CEO of ANGIOGENEX, INC.?
Robert Benezra is the chief executive officer of ANGIOGENEX, INC. (AGGX).
What therapeutic areas does ANGIOGENEX, INC. focus on?
ANGIOGENEX, INC. develops therapies across Oncology, Ophthalmology.
923 companies304,846 SEC filings22,651 clinical trials100% citation-verification pass rate (7d)How we verify →
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.